Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities. SAHA is marketed under the name Vorinostat, brand name Zolinza, for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It has been used to treat Sézary's disease.
1 edit since May 19, 2008. Last edited Jul 27, 2008 by Carlo Banez (49).
This Compound Monograph is licensed under the GNU Free Documentation License and uses material from the Wikipedia article Vorinostat. See this site's terms for details.